ESMO26: The “paradigm-shifting” readouts in endometrial & ovarian cancer

We bring you the highlights in endometrial and ovarian cancer from ESMO 2026, with readouts from MSD, AstraZeneca, Genmab and GSK. Clinical Trials Arena highlights the key trial readouts in endometrial and ovarian cancer from the 2026 ESMO Congress in Madrid. Clinical Trials Arena brings you the highlights in women’s cancer from ESMO 2026. Credit: Anastasiia Usenko / Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free Clinical Trials Arena profile, you can: Experience unmatched clarity with a single platform…

Source: Clinical Trials Arena